Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell - lineage antigen expression: experience from a tertiary cancer care center

Abstract Introduction Flow cytometric immunophenotyping (FCI) plays a major role in diagnosing hematologic malignancies. In patients diagnosed with precursor B-lineage acute lymphoblastic leukemia (B-ALL), expression of certain non-lineage/cross lineage antigens is of prognostic and cytogenetic relevance. There is a paucity of studies that have comprehensively analyzed the clinical and laboratory profiles of B-ALL patients showing aberrant T/natural killer (NK) cell antigen expression. Materials and methods This is a prospective study where 152 consecutive B-ALL patients were analyzed for aberrant expression of T/NK cell antigens (CD1a, CD5, CD4, CD7, CD8 and CD56) by FCI. The clinical and laboratory profile of these T/NK-cell antigen-expressing B-ALL patients was statistically analyzed against conventional B-ALL patients. Results In our B-ALL cohort, CD5, CD7 and CD56 expression were observed in one, six and nine patients, respectively. CD56-expressing B-ALL patients were predominantly children (89%) and presented as standard clinical risk (p = 0.010) disease with frequent ETV6-RUNX1 fusion (p = 0.021) positivity. On the contrary, CD7-expressing B-ALL patients were adolescent-young adult/adult-age skewed (83%) and had an adverse cytogenetic profile (p = 0.001), especially for the frequent presence of BCR-ABL1 fusion (p = 0.004) and KMT2A rearrangement (p = 0.045). CD7-expressing B-ALL patients had inferior event-free survival (p = 0.040) than their CD56-expressing counterparts, but there was no significant difference in the overall survival (p = 0.317). Conclusion In comparison to conventional B-ALL patients, there are significant differences in the age, cytogenetic profile and event-free survival of T/NK-cell antigen-expressing B-ALL patients.

Saved in:
Bibliographic Details
Main Authors: Bommannan,Karthik, Arumugam,Jhansi Rani, Radhakrishnan,Venkatraman, Kalaiyarasi,Jayachandran Perumal, Mehra,Nikita, Sagar,Tenali Gnana, Sundersingh,Shirley
Format: Digital revista
Language:English
Published: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH) 2022
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792022000200143
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S2531-13792022000200143
record_format ojs
spelling oai:scielo:S2531-137920220002001432022-06-08Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell - lineage antigen expression: experience from a tertiary cancer care centerBommannan,KarthikArumugam,Jhansi RaniRadhakrishnan,VenkatramanKalaiyarasi,Jayachandran PerumalMehra,NikitaSagar,Tenali GnanaSundersingh,Shirley CD56 positive precursor B lineage acute lymphoblastic leukemia CD7 positive precursor B lineage acute lymphoblastic leukemia Precursor B lineage acute lymphoblastic leukemia Abstract Introduction Flow cytometric immunophenotyping (FCI) plays a major role in diagnosing hematologic malignancies. In patients diagnosed with precursor B-lineage acute lymphoblastic leukemia (B-ALL), expression of certain non-lineage/cross lineage antigens is of prognostic and cytogenetic relevance. There is a paucity of studies that have comprehensively analyzed the clinical and laboratory profiles of B-ALL patients showing aberrant T/natural killer (NK) cell antigen expression. Materials and methods This is a prospective study where 152 consecutive B-ALL patients were analyzed for aberrant expression of T/NK cell antigens (CD1a, CD5, CD4, CD7, CD8 and CD56) by FCI. The clinical and laboratory profile of these T/NK-cell antigen-expressing B-ALL patients was statistically analyzed against conventional B-ALL patients. Results In our B-ALL cohort, CD5, CD7 and CD56 expression were observed in one, six and nine patients, respectively. CD56-expressing B-ALL patients were predominantly children (89%) and presented as standard clinical risk (p = 0.010) disease with frequent ETV6-RUNX1 fusion (p = 0.021) positivity. On the contrary, CD7-expressing B-ALL patients were adolescent-young adult/adult-age skewed (83%) and had an adverse cytogenetic profile (p = 0.001), especially for the frequent presence of BCR-ABL1 fusion (p = 0.004) and KMT2A rearrangement (p = 0.045). CD7-expressing B-ALL patients had inferior event-free survival (p = 0.040) than their CD56-expressing counterparts, but there was no significant difference in the overall survival (p = 0.317). Conclusion In comparison to conventional B-ALL patients, there are significant differences in the age, cytogenetic profile and event-free survival of T/NK-cell antigen-expressing B-ALL patients.info:eu-repo/semantics/openAccessAssociação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)Hematology, Transfusion and Cell Therapy v.44 n.2 20222022-04-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792022000200143en10.1016/j.htct.2020.08.012
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Bommannan,Karthik
Arumugam,Jhansi Rani
Radhakrishnan,Venkatraman
Kalaiyarasi,Jayachandran Perumal
Mehra,Nikita
Sagar,Tenali Gnana
Sundersingh,Shirley
spellingShingle Bommannan,Karthik
Arumugam,Jhansi Rani
Radhakrishnan,Venkatraman
Kalaiyarasi,Jayachandran Perumal
Mehra,Nikita
Sagar,Tenali Gnana
Sundersingh,Shirley
Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell - lineage antigen expression: experience from a tertiary cancer care center
author_facet Bommannan,Karthik
Arumugam,Jhansi Rani
Radhakrishnan,Venkatraman
Kalaiyarasi,Jayachandran Perumal
Mehra,Nikita
Sagar,Tenali Gnana
Sundersingh,Shirley
author_sort Bommannan,Karthik
title Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell - lineage antigen expression: experience from a tertiary cancer care center
title_short Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell - lineage antigen expression: experience from a tertiary cancer care center
title_full Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell - lineage antigen expression: experience from a tertiary cancer care center
title_fullStr Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell - lineage antigen expression: experience from a tertiary cancer care center
title_full_unstemmed Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell - lineage antigen expression: experience from a tertiary cancer care center
title_sort precursor b-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and t cell - lineage antigen expression: experience from a tertiary cancer care center
description Abstract Introduction Flow cytometric immunophenotyping (FCI) plays a major role in diagnosing hematologic malignancies. In patients diagnosed with precursor B-lineage acute lymphoblastic leukemia (B-ALL), expression of certain non-lineage/cross lineage antigens is of prognostic and cytogenetic relevance. There is a paucity of studies that have comprehensively analyzed the clinical and laboratory profiles of B-ALL patients showing aberrant T/natural killer (NK) cell antigen expression. Materials and methods This is a prospective study where 152 consecutive B-ALL patients were analyzed for aberrant expression of T/NK cell antigens (CD1a, CD5, CD4, CD7, CD8 and CD56) by FCI. The clinical and laboratory profile of these T/NK-cell antigen-expressing B-ALL patients was statistically analyzed against conventional B-ALL patients. Results In our B-ALL cohort, CD5, CD7 and CD56 expression were observed in one, six and nine patients, respectively. CD56-expressing B-ALL patients were predominantly children (89%) and presented as standard clinical risk (p = 0.010) disease with frequent ETV6-RUNX1 fusion (p = 0.021) positivity. On the contrary, CD7-expressing B-ALL patients were adolescent-young adult/adult-age skewed (83%) and had an adverse cytogenetic profile (p = 0.001), especially for the frequent presence of BCR-ABL1 fusion (p = 0.004) and KMT2A rearrangement (p = 0.045). CD7-expressing B-ALL patients had inferior event-free survival (p = 0.040) than their CD56-expressing counterparts, but there was no significant difference in the overall survival (p = 0.317). Conclusion In comparison to conventional B-ALL patients, there are significant differences in the age, cytogenetic profile and event-free survival of T/NK-cell antigen-expressing B-ALL patients.
publisher Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)
publishDate 2022
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792022000200143
work_keys_str_mv AT bommannankarthik precursorblineageacutelymphoblasticleukemiapatientswithaberrantnaturalkillercellandtcelllineageantigenexpressionexperiencefromatertiarycancercarecenter
AT arumugamjhansirani precursorblineageacutelymphoblasticleukemiapatientswithaberrantnaturalkillercellandtcelllineageantigenexpressionexperiencefromatertiarycancercarecenter
AT radhakrishnanvenkatraman precursorblineageacutelymphoblasticleukemiapatientswithaberrantnaturalkillercellandtcelllineageantigenexpressionexperiencefromatertiarycancercarecenter
AT kalaiyarasijayachandranperumal precursorblineageacutelymphoblasticleukemiapatientswithaberrantnaturalkillercellandtcelllineageantigenexpressionexperiencefromatertiarycancercarecenter
AT mehranikita precursorblineageacutelymphoblasticleukemiapatientswithaberrantnaturalkillercellandtcelllineageantigenexpressionexperiencefromatertiarycancercarecenter
AT sagartenalignana precursorblineageacutelymphoblasticleukemiapatientswithaberrantnaturalkillercellandtcelllineageantigenexpressionexperiencefromatertiarycancercarecenter
AT sundersinghshirley precursorblineageacutelymphoblasticleukemiapatientswithaberrantnaturalkillercellandtcelllineageantigenexpressionexperiencefromatertiarycancercarecenter
_version_ 1756442083764207616